Irving J. Arons September 2, 2010 (Version 3, Updated September 14, 2010) I recently came across an interesting news release from International Stem Cell Corporation (ISCO) announcing that it had formed a new business unit, Cytovis, to focus on stem cell programs in ophthalmology, including CytoCor for the cornea and CytoRet for the retina. That [Read More]
Category: Research and Developments
Spikes in IOP May Result From Particulate Matter in Avastin
by Dan Roberts In a presentation to Hawaiian Eye 2010, Malik Y. Kahook, MD, said that Avastin (bevacizumab) stored for long periods of time shows evidence of increased large particulate matter. This debris can block the eye’s trabecular network and lead to increased intraocular pressure (IOP) in patients being treated with the drug for wet [Read More]
Summary of Research and Developments in Macular Degeneration: 2009-2010
by Dan Roberts June 10, 2010 Introduction If I were to describe the past twelve months in a word, it would be “progress.” No spectacular breakthroughs have occurred during that time to make big news in the AMD world, but a lot of persistent work has been reaping promising results. moving us ever closer to [Read More]
Genetic testing sheds light on degenerative eye disease
Press Release February 13, 2007 Updated 5/16/2010 ANN ARBOR, Mich. — Genetic testing for eye disease is providing vital information about complex retinal diseases, especially when used to confirm a clinician’s diagnosis. In a newly published review of such tests that were conducted over a five-year period at the University of Michigan Kellogg Eye Center, [Read More]
Study Shows Lucentis and Avastin to be Equal
by Dan Roberts February 3, 2010 Investigators at Kaiser Permanente Southern California in Pasadena reported in the February 2010 issue of Ophthalmology that Avastin and Lucentis performed equally in recent testing. In an indirect comparison of the two drugs, study author Dr. Donald Fong and coauthors reviewed the records of 452 patients treated for wet [Read More]